Table 1.
List of most prominent ongoing clinical trials.
| Registration number | Title of the study | Type of study | Type of neuroprotection | Primary outcome | Results |
|---|---|---|---|---|---|
| NCT04061577 | Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke Before and After Thrombectomy (TESSERACT-BA) | RCT | Direct current stimulation | Primary safety outcome- rate of symptomatic intracranial hemorrhage | Ongoing |
| NCT03481777 | Remote ischemic conditioning in patients with acute stroke (RESIST) | RCT | RIC | Clinical outcome (mRS) at 3 months in acute stroke patients | Ongoing |
| NCT02767778 | Low-frequency Pulsed Electromagnetic Fields (ELF-MF) as Treatment for Acute Ischemic Stroke (I-NIC) | RCT | Low frequency pulsed electromagnetic fields | Change in the volume of the ischemic lesion measured by MRI | Ongoing |
| NCT04266639 | Rheo-erythrocrine dysfunction as a biomarker for RIC treatment in acute ischemic stroke (ENOS) | RCT | Rheo-erythrocrine dysfunction as a biomarker for RIC treatment | Red blood cell deformability will serve as a biomarker of the conditioning response and predictor of the clinical outcome in stroke patients | Ongoing |
| NCT04554797 | Regional hypothermia in combination with endovascular thrombectomy in acute ischemic stroke (RE-HIBER) | RCT | Regional hypothermia | Rate of any major adverse events | Ongoing |
| NCT03375762 | REMOTE ischemic perconditioning among acute ischemic stroke patients (REMOTE-CAT) | RCT | Remote ischemic preconditioning | Dependency based on mRS through first 3 months | Ongoing |
| NCT03347786 | Verapamil for neuroprotection in stroke | Single group assignment | Verapamil | Serious adverse event | Ongoing |
| NCT03915431 | A Study of NCS-01 in patients with acute ischemic stroke | RCT | NCS-01 infusion | Number of participants with adverse events -Safety by Incidence of Treatment-Emergent Adverse Events | Ongoing |
| NCT03876119 | Intraarterial alteplase vs. placebo after mechanical thrombectomy (CHOICE) | RCT | Intra-arterial alteplase | The primary outcome will be the proportion of patients with a mRS 0 to 1 at 90 days | Ongoing |
| NCT02453373 | Helping stroke patients with thermosuit cooling (SISCO) | Non-randomized clinical trial | Rapid induction of therapeutic hypothermia (32-34°C) using the Life Recovery Systems ThermoSuit System Magnesium sulfate, intravenous administration | Feasibility of cooling as indicated by percentage of patients cooled to target within 1 h of start of cooling. Neurological outcome as indicated by NIHSS Safety of the cooling treatment as indicated by rates of significant adverse events Neurological outcome as indicated by mRS score Change in neurological outcome as indicated by NIHSS Change in neurological status as indicated by mRS |
Ongoing |
| NCT03804060 | REperfusion with cooling in cerebral acute ischemia II (RECCLAIM-II) | RCT | Cooling with the ZOLL Circulation Proteus catheter and the ZOLL Intravascular Temperature Management system to initiate and maintain hypothermia for 6 h as an adjunct to endovascular recanalization | Percentage of test arm patients achieving target temperature Mean door-to-recanalization time Rate of hemorrhagic conversion in each arm within 36 h of recanalization |
Ongoing |
| NCT03284463 | Safety and efficacy of glibenclamide combined with Rt-PA in acute cerebral embolism (SE-GRACE) | RCT | Glibenclamide is administered with a loading dose of 1.25 mg within 10 h of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 h for 5 days | Functional outcome: The proportion of mRS of 0 to 2 points | Ongoing |
| NCT02864953 | Phase 3 Study to evaluate the efficacy and safety of intravenous BIIB093 (Glibenclamide) for severe cerebral edema following large hemispheric infarction (CHARM) | RCT | Intravenous glibenclamide | Percentage of participants with improvement in functional outcome at day 90 Assessed via the mRS | Ongoing |
| NCT03753555 | The effect of intensive statin in ischemic stroke with intracranial atherosclerotic plaques (INSIST-HRMRI) | RCT | Atorvastatin Calcium 20 mg every day for 12 months in the comparator group. Atorvastatin Calcium 40–80 mg every day for 6 months | Changes in remodeling index after the statin treatment Changes in plaque burden after the statin treatment Changes plaque composition in after the statin treatment |
Ongoing |
| NCT04275180 | Clinical study of argatroban in the treatment of acute progressive ischemic stroke | RCT | Argatroban plus standard medical treatment | Proportion of patients with a 3-month mRS score ≤ 3 | Ongoing |
| NCT04425590 | The benefit of add on DLBS1033 for ischemic stroke patient | RCT | DLBS 1033 (disolf) 490 mg tablet 3 times daily | Improvement in mRS scores at hospital discharge Improvement in mRS scores at 30 days Improvement in NIHSS scores at hospital discharge Improvement in NIHSS scores at 30 days Improvement in BI scores at hospital discharge Improvement in BI scores at 30 days |
Ongoing |
| NCT03724110 | Telestroke for comprehensive transient ischemic attack care in acute stroke ready hospitals (TELECAST-TIA) | Cohort study | Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) | Composite score of TIA treatment (%) | Ongoing |
| NCT03868007 | Protective effects of RIC in elderly with acute ischemic stroke complicating acute coronary syndrome (RIC-ACS) | RCT | The RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mm Hg for 5 cycles of 5 min followed by 5 min of relaxation of the cuffs | Death rate | Ongoing |
| NCT03993236 | Study on rosuvastatin + ezetimibe and rosuvastatin for LDL-C goal in patients with recent ischemic stroke | RCT | The experimental group is orally administered with rosuvastatin 10 mg plus ezetimibe 10 mg combination once daily for 90 days | The percentage of patients with LDL-C decreased more than 50% at 90 days (±14 days) compared to baseline | Ongoing |
| NCT03287076 | Trial of EXenatide in Acute Ischaemic Stroke (TEXAIS) | RCT | Patients will receive exenatide injections | Improved neurologic outcome | Ongoing |
| NCT03635177 | Effect of remote ischemic conditioning on vascular health in stroke patients (VISP) | RCT | The participant will conduct remote ischemic preconditioning by use of an automated cuff device placed on the upper arm which inflates to 200 mm Hg and occludes blood flow The procedure is conducted on one arm 4 x 5 min per day Each 5 min occlusion period is interspersed by 5 min | Assessment of brachial artery dilation after 5 min occlusion of upper arm by cuff | Ongoing |
BI, Barthel index; LDL-C, low-density lipoprotein cholesterol; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; RCT, randomized controlled trial; RIC, remote ischemic conditioning; rtPA, recombinant tissue plasminogen activator; TIA, transient ischemic attack.